Bristol Myers Gets Europe OK for Zeposia in Ulcerative Colitis
November 23 2021 - 7:44AM
Dow Jones News
By Colin Kellaher
Bristol Myers Squibb Co. on Tuesday said the European Commission
approved the expanded use of its multiple-sclerosis drug Zeposia
for the treatment of adults with moderately to severely active
ulcerative colitis, a chronic inflammatory bowel disease.
The New York biopharmaceutical company said the approval covers
patients who have had an inadequate response, lost response or were
intolerant to either conventional therapy or a biologic agent.
Bristol Myers last year received U.S. and European approval for
Zeposia in adults with relapsing forms of multiple sclerosis and
earlier this year received U.S. Food and Drug Administration
approval for the drug ulcerative colitis. The company is also
evaluating the drug as a treatment for Crohn's disease.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 23, 2021 07:29 ET (12:29 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Sep 2023 to Sep 2024